HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They presently have a $80.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 107.63% from the stock’s current price.

CLDX has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. TD Cowen started coverage on shares of Celldex Therapeutics in a report on Wednesday, December 20th. They issued an “outperform” rating on the stock. Finally, Guggenheim upped their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average target price of $66.00.

Celldex Therapeutics Stock Down 2.8 %

Celldex Therapeutics stock opened at $38.53 on Wednesday. Celldex Therapeutics has a 52 week low of $22.11 and a 52 week high of $53.18. The firm’s 50-day simple moving average is $42.03 and its 200 day simple moving average is $35.73. The firm has a market capitalization of $2.15 billion, a PE ratio of -13.24 and a beta of 1.49.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. On average, research analysts expect that Celldex Therapeutics will post -2.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd increased its stake in shares of Celldex Therapeutics by 57.9% during the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 511 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 805 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Celldex Therapeutics by 604.9% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 1,869 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in Celldex Therapeutics by 78.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 1,226 shares in the last quarter. Finally, Strs Ohio increased its position in Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 1,300 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.